Monrovia, CA, August 09, 2008 --(PR.com
)-- GTCbio just announced the scheduling of its 4th annual Neurodegenerative Diseases Drug Discovery Conference on October 9-10, 2008 in Philadelphia, PA.
Neurodegenerative diseases continue to play an enormous role in the growing public health problem, disrupting the quality of life of millions of people and costing society billions of dollars annually.
Nonetheless, in the last few years, there has been great progress in the development of novel therapeutic approaches to treat Alzheimer’s, Parkinson’s, Huntington’s, Multiple Sclerosis, Stroke and various other neurodegenerative diseases. There have also been significant developments in our understanding of the genetics, the molecular mechanisms and signaling pathways contributing to neuronal dysfunction, neurotoxicity and pathology.
At the Neurodegenerative Diseases Drug Discovery forum, leading scientists and experts will discuss these latest breakthroughs, new drug targets, new models, the development of new biomarkers, imaging modalities, improved clinical trial designs and several other novel developments and therapeutics to combat neurodegenerative conditions.
Keynote presenters include Eric Karran, Chief Scientific Officer of the Neurodegenerative Diseases Drug Hunting Team at Eli Lilly & Company and William Z. Potter, Vice President of Translational Neuroscience at
Merck & Co.
For more information on attending, presenting a poster, or sponsoring, please visit http://gtcbio.com/conferenceDetails.aspx?id=133.
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: Nina Tran, Senior Conference Producer, GTCbio (626) 256-6405, (626) 256-6460 fax, Nina.Tran@gtcbio.com